What did @valerieorsoni actually say?
The core argument here is that BPC-157 lacks large US clinical trials not because it is scientifically invalid, but because no pharmaceutical company will fund a $100M+ FDA approval pathway for an unpatentable peptide. She also argues that dismissing compounds solely because they are absent from clinicaltrials.gov confuses a regulatory database with the totality of scientific evidence.
She names Dr. Predrag Sikiric, the Croatian researcher who has studied BPC-157 since the early 1990s, and draws a contrast with semaglutide, which benefits from billions in commercial backing. Her closing point: evidence-based medicine requires understanding who funds the evidence, not just whether a drug appears in one registry.
Does the science back this up?
On the funding argument, she is largely correct. On BPC-157's readiness for clinical use, she is far more optimistic than the data justifies.
The funding asymmetry argument is well-documented in the literature. Kesselheim et al. (2015, JAMA) showed that industry-sponsored trials are substantially more likely to reach phase 3 simply because of financial capacity, not because the underlying science is stronger. The 2007 FDA Amendments Act did expand mandatory US trial registration requirements, making pre-2007 research genuinely less visible on clinicaltrials.gov, as she notes.
However, the preclinical evidence for BPC-157 is almost entirely animal-based. Reviews by Sikiric et al. (2018, Current Pharmaceutical Design) document promising results in rodent models for tendon healing, gut protection, and angiogenesis. But animal models, particularly for complex healing processes, have a notoriously poor translation rate to human outcomes. There are no published peer-reviewed phase 1, 2, or 3 human trials for BPC-157. Zero. That is not just a funding gap. That is a missing safety and efficacy dataset in humans.
What did they get wrong (or right)?
She gets the economics right. She gets the epistemology partly right. But she glosses over a genuinely important distinction.
Saying that a compound is "published in PubMed but simply not registered on clinicaltrials.gov" implies a body of human clinical evidence that does not exist for BPC-157. PubMed contains the animal studies. Those matter as hypothesis-generating research, but they are not clinical evidence. The framing implies the two are closer in evidentiary weight than they are.
She is also correct that semaglutide's trial volume reflects its commercial market. That is not conspiracy, it is how pharmaceutical economics work, and saying so out loud is useful.
- Credit: The critique of clinicaltrials.gov as a compliance tool, not a scientific completeness metric, is valid and underappreciated.
- Credit: The pre-2007 registration point is factually accurate and relevant.
- Problem: Presenting robust preclinical data as a near-equivalent to clinical evidence misleads the audience about where BPC-157 actually sits on the evidence spectrum.
- Problem: No acknowledgment that the absence of human safety data is a genuine clinical concern, not just a bureaucratic gap.
What should you actually know?
BPC-157 is an interesting research compound with a real preclinical signal. It is not a validated human therapy. Those are not the same thing.
The peptide remains unscheduled in the US but is not FDA-approved for any indication. It is classified as a "bulk drug substance" under scrutiny by the FDA, which issued guidance in 2023 restricting its use in compounded preparations. That regulatory action exists precisely because human safety data is thin, not because regulators are ignoring the Croatian literature.
If you are considering BPC-157, the honest picture is this: animal models suggest potential in gut and tendon contexts, human pharmacokinetic data is sparse, long-term safety in humans is unknown, and the compound is being administered in doses extrapolated from rodent studies. The funding argument explains why we do not have phase 3 trials. It does not substitute for them.
Orsoni's broader media literacy point, that you should ask who funded a study and why, is genuinely good scientific thinking. Applying it only in one direction, to dismiss skepticism about underfunded compounds, is where the argument gets selective.